Business ❯ Pharmaceutical Industry

Drug Manufacturers

Pricing Strategies Novo Nordisk Eli Lilly Pfizer Market Dynamics AstraZeneca Pricing Agreements Kenvue Eli Lilly and Novo Nordisk Cost Reduction Strategies

White House Launches TrumpRx.gov, a Portal to Discounted Prescription Drugs

The government portal directs cash‑paying patients to manufacturers’ discounts negotiated under most‑favored‑nation pricing.

White House Launches TrumpRx Portal to Steer Patients to Lower-Priced Drugs

GLP-1 Weight-Loss Push Intensifies as Novo Leads Ads and Wegovy Pill Drives Telehealth Uptake

AbbVie Strikes Trump Drug-Pricing Deal, Pledges $100 Billion, Wins 3-Year Tariff Reprieve

Oregon Sues Insulin Makers and PBMs, Alleging $900 Million Pricing Scheme

Indiana Sues Eli Lilly, Alleging Scheme to Inflate Insulin Prices

Drugmakers to Lift 2026 U.S. List Prices on 350 Branded Medicines

CMS Unveils Voluntary BALANCE Program to Lower GLP-1 Costs for Medicare and Medicaid

Trump Claims Tariff Threat Moved Macron on Drug Prices, France Disputes Account

White House Adds 9 Pharma Deals, Extending Drug-Price Pacts to 14 Manufacturers

Trump Adds Nine Pharma Giants to Drug Pricing Deals, Reaching 14 Signatories as TrumpRx Nears Launch

Medicare’s First Negotiated Drug Prices Take Effect Jan. 1, Cutting 2026 Costs

FDA Adds Brain Tumor Warning to Two Depo‑Provera Injections

Germany’s Top Court Weighs AstraZeneca Liability Over Alleged Vaxzevria Injury

Trump Touts 'Affordability President' Rebrand, Claims Drug Prices Fell 500%–700%

Medicare Sets 2027 Prices for 15 High-Cost Drugs, Including Ozempic

Judge Approves Revised Purdue–Sackler Opioid Settlement Requiring Up To $7 Billion

White House Clinches GLP-1 Price Deal as Lilly Sets Zepbound and Pill Pricing

White House Finalizes GLP-1 Price Deal With Lilly and Novo, Setting $50 Medicare Copays

U.S. Strikes Price-Cut Deals With Novo Nordisk and Eli Lilly for GLP‑1s, With Medicare Pilot in 2026